New Study Adds Vytorin Woes For Merck, Schering

Law360, New York (July 22, 2008, 12:00 AM EDT) -- Merck & Co. and Schering-Plough Corp. are facing an increasingly uphill battle to ward off concerns over their jointly marketed cholesterol treatment Vytorin, with a new study reportedly showing that the blockbuster drug is no more effective than a placebo in treating patients with serious heart conditions.

The results of the study, announced Monday by a team of European researchers, found that Vytorin did not prevent complications from aortic stenosis, a condition in which blood flow to the heart is blocked, leading to congestive heart failure...
To view the full article, register now.